IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma

PURPOSE: Glioblastoma (GBM) is the most aggressive primary brain tumor in adults with a median survival of 15–20 months. Numerous approaches and novel therapeutics for treating GBM have been investigated in the setting of phase III clinical trials, including a recent analysis of the immune checkpoin...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Main Authors: Ladomersky, Erik, Zhai, Lijie, Lenzen, Alicia, Lauing, Kristen L., Qian, Jun, Scholtens, Denise M., Gritsina, Galina, Sun, Xuebing, Liu, Ye, Yu, Fenglong, Gong, Wenfeng, Liu, Yong, Jiang, Beibei, Tang, Tristin, Patel, Ricky, Platanias, Leonidas C., James, C. David, Stupp, Roger, Lukas, Rimas V., Binder, David C., Wainwright, Derek A.
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5984675/
https://ncbi.nlm.nih.gov/pubmed/29500275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-3573
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares